|
시장보고서
상품코드
2050982
약물유전체학 시장 : 기술별, 용도별, 최종사용자별, 지역별Pharmacogenomics Market, By Technology, By Application, By End User By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
약물유전체학 시장은 2026년에 215억 7,000만 달러로 추정되고, 2033년까지 479억 8,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 12.1%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 215억 7,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 12.10% | 2033년 시장 규모 예측 : | 479억 8,000만 달러 |
약물유전체학은 유전자가 약물에 대한 사람의 반응에 어떤 영향을 미치는지 분석하는 과학의 한 분야입니다. 이는 각 개인의 유전적 구성이 체내 약물 대사 및 반응에 영향을 미칠 수 있다는 원리를 기반으로 합니다. 유전자 스크리닝 및 검사 기술의 발전과 함께, 약물유전체학은 환자 개개인의 유전자 프로파일을 고려한 개별화된 처방 접근법 개발을 목표로 하고 있습니다. 이를 통해 환자의 특정 요구에 맞는 효과적인 의약품을 선택할 수 있으며, 시행착오에 의한 처방과 약물 부작용을 줄일 수 있습니다. 약물 치료 결과를 최적화하기 위한 이 접근법의 임상적 유용성을 인정하는 의료 시스템이 늘어남에 따라 세계 약물유전체학 시장은 향후 몇 년 동안 크게 성장할 것으로 예측됩니다.
시장 역학
세계 약물유전체학 시장은 약물 부작용 발생률 증가, 맞춤형 의료에 대한 수요 증가, 동반진단의 확산 등의 요인에 의해 주도되고 있습니다. 또한, 약물유전체학 기법을 이용한 표적치료제 개발을 위한 제약사들의 막대한 연구개발비도 시장 성장을 견인하고 있습니다. 그러나 유전자 검사의 임상적 타당성 검증과 표준화의 부족은 임상현장에서의 광범위한 도입을 가로막는 과제로 남아있습니다. 유전자 스크리닝과 관련된 데이터 프라이버시 및 윤리적 문제도 시장 확대를 가로막는 요인으로 작용하고 있습니다. 기회로는 약물유전학 검사 및 프로파일링을 임상시험 및 규제 당국의 승인 절차에 통합하는 것을 들 수 있습니다. 특히 보급률이 낮은 신흥 시장을 위해 저렴한 가격의 약물유전학 진단 키트와 서비스를 개발하는 것도 시장 성장의 지름길입니다.
본 조사의 주요 특징
- 이 조사에서는 각 부문의 잠재적인 수익 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 약물유전체학 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이번 조사에 포함된 주요 기업으로는 Thermo Fisher Scientific, F. Hoffman-La Roche, Falmigen, Abbott, Agilent Technologies, QIAGEN, GE Healthcare, Empire Genomics, BioRad Laboratories, Oxford Nanopore Technologies, PerkinElmer, Myriad Genetics, Illiad Genetics, Inc. 바이오 래드 연구소, 옥스포드 나노포어 테크놀로지스, 퍼킨엘머, 마일리아드 제네틱스, 일루미나, 매크로젠, BGI 제노믹스, 유로핀 사이언티픽, 맵마이유전체, 그리고 인비테이아 코퍼레이션이 포함됩니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 입각한 의사결정을 내릴 수 있도록 도와줄 것입니다.
- 세계 약물유전체학 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 약물유전체학 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 약물유전체학 시장 : 기술별, 2021년-2033년
제5장 세계의 약물유전체학 시장 : 용도별, 2021년-2033년
제6장 세계의 약물유전체학 시장 : 최종사용자별, 2021년-2033년
제7장 세계의 약물유전체학 시장 : 지역별, 2021년-2033년
제8장 경쟁 구도
제9장 애널리스트의 견해
제10장 참고 문헌 및 조사 방법
LSH 26.06.16Pharmacogenomics Market is estimated to be valued at USD 21.57 Bn in 2026 and is expected to reach USD 47.98 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 21.57 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.10% | 2033 Value Projection: | USD 47.98 Bn |
Pharmacogenomics is the branch of science that analyzes how genes affect a person's response to medications. It works on the principle that each person's genetic make-up can influence how their body metabolizes and responds to drugs. With advancements in genetic screening and testing technologies, pharmacogenomics aims to develop personalized prescription approaches that factor in patients' individual genetic profiles. This enables the selection of effective medicines tailored to patients' specific needs while reducing trial-and-error prescribing practices and adverse drug reactions. The global pharmacogenomics market is expected to grow significantly in the coming years as more healthcare systems recognize the clinical utility of this approach in optimizing pharmacotherapy outcomes.
Market Dynamics
The global pharmacogenomics market is driven by factors such as rising incidences of adverse drug reactions, growing need for personalized medicine, and increasing uptake of companion diagnostics. High research and development expenditures by pharmaceutical companies to develop targeted therapies using pharmacogenomics approaches are also fueling the market growth. However, lack of clinical validation and standardization of genetic tests remains a challenge limiting widespread clinical adoption. Data privacy and ethical concerns related to genetic screening further hamper market expansion. Opportunities lie in incorporating pharmacogenomic testing and profiling into drug trials and regulatory approval processes. Developing affordable pharmacogenetic diagnostic kits and services especially for underpenetrated emerging markets also presents an avenue for market growth.
Key Features of the Study
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global pharmacogenomics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this includes Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Pharmigene, Abbott, Agilent Technologies, Inc., QIAGEN, GE HealthCare, Empire Genomics, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies plc., PerkinElmer Inc. , Myriad Genetics, Inc., Illumina, Inc., Macrogen, Inc. , BGI Genomics, Eurofins Scientific, MapMyGenome, and Invitae Corporation.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global pharmacogenomics market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmacogenomics market.
Market Segmentation
- Technology Insights (Revenue, USD Bn, 2021 - 2033)
- DNA Sequencing
- Microarray
- Polymerase Chain Reaction
- Electrophoresis
- Mass Spectrometry
- Others
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Cardiovascular Diseases
- Infectious Diseases
- Oncology
- Neurological Diseases
- Pain Management
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals & Clinics
- Research Institutions and Academic Institutes
- Diagnostic Laboratories
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Pharmigene
- Abbott
- Agilent Technologies, Inc.
- QIAGEN
- GE HealthCare
- Empire Genomics, Inc.
- Bio-Rad Laboratories, Inc.
- Oxford Nanopore Technologies plc.
- PerkinElmer Inc.
- Myriad Genetics, Inc.
- Illumina, Inc.
- Macrogen, Inc.
- BGI Genomics
- Eurofins Scientific
- MapMyGenome
- Invitae Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Manufacturer Revenue
- Acquisitions and Partnerships Scenario
- Product Launches/Approvals
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Pharmacogenomics Market, By Technology, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- DNA Sequencing
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Microarray
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Polymerase Chain Reaction
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Electrophoresis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Mass Spectrometry
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Pharmacogenomics Market, By Application, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cardiovascular Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Infectious Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oncology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Neurological Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pain Management
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Pharmacogenomics Market, By End User, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals & Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Research Institutions and Academic Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Pharmacogenomics Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pharmigene
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GE HealthCare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Empire Genomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bio-Rad Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Oxford Nanopore Technologies plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PerkinElmer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Myriad Genetics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Macrogen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BGI Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eurofins Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- MapMyGenome
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Thermo Fisher Scientific Inc.
9. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
